Key Findings
MilliporeSigma announced that its FemtoQuest system, an enhanced 3rd generation instrument incorporating Single Molecule Counting (SMC) technology, significantly boosts researchers’ capability to detect ultra-low levels of biomarkers with exceptional sensitivity and speed. This system holds particular promise for drastically shortening diagnostic times, especially in urgent situations like sepsis, where rapid pathogen identification is critical.
Technical & Clinical Details
The FemtoQuest system is centered around a BioMEMS (Bio-Micro-Electro-Mechanical System) sensor, often described as a ‘fingernail-sized Lab-on-a-chip,’ which enables highly efficient analysis from limited sample volumes. SMC technology allows detection at the individual molecule level, making it possible to capture ultra-low concentrations of biomarkers that were challenging for conventional techniques. The most remarkable capability of this instrument is its ability to simultaneously test up to 250 genetic characteristics (e.g., viral or bacterial DNA/RNA) within just 15 minutes. This capability is particularly valuable in clinical scenarios requiring rapid identification of multiple pathogens, such as in the diagnosis of sepsis, a severe infection. Sepsis is a race against time, and rapid diagnosis directly leads to timely and appropriate treatment initiation, which can significantly improve patient outcomes and save lives.
Background & Context
In clinical diagnostics, especially in the field of infectious diseases, prompt and accurate identification of pathogens is essential for developing effective treatment strategies. However, many conventional testing methods are time-consuming, require complex sample preparation, or suffer from insufficient detection sensitivity. These limitations are particularly evident when biomarkers are present at extremely low concentrations or when numerous pathogens need to be considered simultaneously. The combination of SMC technology and BioMEMS integrated into the FemtoQuest system overcomes these challenges, accelerating and increasing the sensitivity of the diagnostic process, thereby significantly contributing to the advancement of personalized medicine and precision diagnostics.
Strategic Significance & Outlook
MilliporeSigma’s FemtoQuest system is poised to bring significant transformation not only as a research tool but also potentially to clinical diagnostics. Its ability to rapidly multiplex detect ultra-low level biomarkers holds promise for a wide range of medical applications, including early diagnosis of infectious diseases, identification of antibiotic-resistant bacteria, cancer screening, and diagnosis of genetic disorders. Particularly, if its technology integration into Point-of-Care Testing (POCT) devices advances, it could contribute to rapid diagnosis outside hospitals and improve healthcare access in resource-limited regions. This is expected to enhance diagnostic accuracy and efficiency, leading to improved patient prognoses and reduced healthcare costs. FemtoQuest is projected to be a key platform driving the forefront of diagnostic technology.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments